Effects of phenylpropanolamine on withdrawal symptoms
|
|
- Nickolas Harper
- 5 years ago
- Views:
Transcription
1 Psychopharmacology (1995) ll9 : Springer-Verlag 1995 Robert C. Klesges - Lisa M. Klesges Margaret DeBon Mary L. Shelton Terry R. Isbell Mary L. Klem Effects of phenylpropanolamine on withdrawal symptoms Received: 19 August 1993 / Final version: 1 November 1994 Abstract A prior report (Klesges et al. 1990) suggested that phewlpropanolamine (PPA) was successful in reducing the smoking withdrawal symptom of weight gain in a sample of women. The current investigation evaluates whether the effects of phenylpropanolamine (PPA; up to 10/day PPA gums) on withdrawal symptoms associated with smoking cessation are specific to weight and weight-related symptoms or whether PPA alleviates withdrawal in general. One hundred and seven adult smokers (56 men, 51 women) were randomly assigned, in this double-blind trial, to chew either 8.33 mg phenylpropanolamine gum or a placebo gum. Subjects were then aided to quit smoking for 4 weeks. PPA did not enhance cessation rates. Results from the 47 subjects who successfully quit smoking indicated that postcessation weight gain and ratings of hunger were significantly reduced in both men and women for those assigned to the PPA group relative to the placebo group. Overall, no effects of PPA relative to placebo were observed for other smoking-related withdrawal symptoms. Thus, although PPA appears to reduce weight gain and alleviate weight-related symptoms, no effects on other withdrawal symptoms were observed. Future research directions are suggested. Key words Phenylpropanolamine Smoking Weight R. C. Klesges (D) The Universities Prevention Center, Department of Psychology, The University of Memphis, Memphis, TN 38152, USA L. M. Klesges Department of Preventive Medicine, Division of Biostatistics and Epidemiology, University of Tennessee, Memphis, TN 38152, USA M. DeBon. M. L. Shelton T. R. Isbell - M. L. Klem The Universities Prevention Center, Department of Psychology, The University of Memphis, Memphis, Tennessee, USA Introduction Although the health consequences and medical costs associated with cigarette smoking are well established (US DHHS 1985, 1990), very few effective strategies for smoking cessation have been developed. Up to 80% of smokers who initially stop smoking relapse within 6 months to a year (Hunt and Bespalec 1974; Schwartz 1987). Major reasons for relapse are that cigarettes are addictive (US DHHS 1988) and cessation from cigarettes produces a reliable set of withdrawal symptoms (Hughes and Hatsukami 1986; Hughes et al. 1991; US DHHS 1988). These symptoms [i.e., craving for cigarettes, anger, anxiety, decreased concentration, restlessness, hunger, and weight gain (US DHHS 1988)] generally appear within 24 h of cessation from smoking, are very intense for at least 2 weeks and then begin to abate (US DHHS, 1990; Hughes et al. 1991). The majority of smoking relapse occurs during the first 2 weeks following cessation coincident with the most severe withdrawal symptoms (US DHHS 1988, 1990). In general, withdrawal symptoms return to or near their baseline levels by 4 weeks postcessation (US DHHS 1990; Hughes et al. 1991), with the exception of craving for a cigarette, hunger, and weight gain. These three symptoms stay" significantly elevated for up to 6 months following cessation (Hughes et al. 1991). A withdrawal symptom of major concern to many smokers, particularly women (Klesges and Klesges 1988), is weight gain. It is clear that most smokers gain weight following cessation but this weight gain rarely poses an independent health risk (US DHHS 1990); however, concerns regarding postcessation weight gain may be both a barrier to cessation and a precipitant of relapse (Klesges and Klesges 1988). In addition, there is emerging evidence that adolescents initiate smoking due to weight-related concerns (Charlton 1984; Camp et al. 1993).
2 86 Given that many smokers are weight conscious, there has been interest in the role of pharmacologic therapy in reducing postcessation weight gain. Studies to date have examined the effect of nicotine replacement on reducing postcessation weight gain (Emont and Cummings 1987; Gross et al. 1989; Tonnesen et al. 1991; Pirie et al. 1992) as well as d-fenfluramine (Spring et al. 1991), fluoxetine (Spring et al. 1992), and phenylpropanolamine (PPA; Klesges et al. 1990). Of the drugs currently being evaluated for reducing post-cessation weight gain, PPA is the only overthe-counter product. PPA, relative to placebo, has been shown to be related to weight loss in both humans (Morgan et al. 1985) and animals (Lasagna 1988), although these effects are generally small (approximately kg/week more than placebo; Greenway 1992). The effects of PPA on postcessation weight gain were recently evaluated by Klesges et al. (1990). Subjects were 57 adult, weight-conscious, female cigarette smokers who were randomly assigned, in a double-blind procedure, to chew gum with PPA, placebo gum, or no gum. After a baseline assessment, subjects were paid to quit smoking for 2 weeks. Fortyone (72%) of the 57 subjects were successful in quitting smoking for the 2-week period. Those receiving PPA gained significantly less weight (mean = 0.09 lb) than either those in the placebo (mean = 1.59 lb) or those in the no gum (mean = t.94 lb) conditions. Dietary intake was also significantly reduced (mean change = 630 kcal) in the PPA group relative to either the no gum (mean decrease = 103 kcal) or the placebo gum (mean increase = 41 kcal) conditions. Finally, those in the PPA group had significantly higher cessation rates (94%, 15 of 16) than those in the no gum (70%, 14 of 20) or the placebo (57%, 12 of 21) groups. Thus, the short-term efficacy of PPA on postcessation weight gain appears promising. An obvious next step is to determine the relative longer term effects of PPA in a less select sample, as the Klesges et al. (1990) study restricted the sample to females who reported being concerned about postcessation weight gain and reported gaining weight in a previous smoking cessation attempt. A second logical step would be to determine if the effects of PPA are specific to weight-related withdrawal symptoms (i.e., weight, hunger) or if PPA has an effect on other withdrawal s)~nptoms (e.g., smoking cravings, concentration). On the one hand, PPA has long been assumed to act peripherally (Lasagna 1988), primarily as an anorectic agent. If this is the case, one should observe significant effects on the hunger-related withdrawal symptoms and no effects on other symptoms related to nicotine withdrawal. On the other hand, there is uncertainty in the literature regarding the mechanism of PPA action, with many investigators arguing that the drug has important central nervous system (CNS) stimulating properties (Morgan 1986). It has been suggested, for example, that PPA is a partial agonist at atpha-adrenergic receptors (Lasagna 1988). If PPA does indeed have CNS properties, one could alternatively argue that PPA may alleviate other aspects of the nicotine withdrawal syndrome (e.g., concentration). Given the uncertainty in the literature on PPA's mechanism(s) of action, the smoking cessation differences (in favor of those receiving PPA) reported by Klesges et al. (1990) become difficult to interpret. If, on the one hand, PPA is acting centrally, it could be argued that many symptoms of withdrawal were affected and higher cessation rates would be observed in those receiving PPA. On the other hand, if PPA is acting peripherally and primarily as an anorectic agent, one would not expect PPA to have an effect on any withdrawal symptoms other than body weight or hunger. Given this, one might observe smoking cessation differences only in individuals extremely concerned about postcessation weight gain. The Klesges et al. (1990) study included only women who (a) were concerned about postcessation weight gain and (b) gained weight in previous cessation attempts. Thus, it is not known whether the cessation rate differences were due to a generalized reduction in the nicotine withdrawal syndrome or whether weight conscious individuals did not relapse to smoking merely because they were not gaining weight. Thus, the purpose of the current investigation was to evaluate the effects of PPA on both body weight and generalized withdrawal symptoms in a cohort of adult male and female smokers who quit smoking for 1 month. A 1-month cessation period was chosen because the majority of smoking-related withdrawal symptoms return to pre-cessation levels by 1 month postcessation (Hughes et al. 1991; 1992). Both men and women were selected for entry into the study and subjects were not screened for concerns related to body weight or postcessation weight gain. The longer-term nature of the study, generalization to men, to those that are not necessarily weight conscious, and most importantly, to all aspects of the nicotine withdrawal syndrome are all unique aspects of the current investigation. Materials and methods Design The current study was a placebo-controlled, double-blind prospective trial of the effect of PPA on withdrawal symptomatology associated with smoking cessation. In its simplest form, the design was a 2 (PPA gum, placebo gum) by 5 (1 week of baseline, 4 weeks of treatment) repeated measures design. The primary outcome variables were smoking withdrawal symptomatology and weight gain. Subjects Subjects were adult male and female cigarette smokers recruited from the community by advertising in the local newspapers. To
3 87 qualify fbr the study, subjects had to be years of age, in good health, and reported to be motivated to stop smoking. Subjects had to report smoking at least 20 cigarettes per day and had to exceed 15 parts-per-million (ppm) of carbon monoxide in expired breath. Subjects were excluded if they had hypertension, heart disease, narcolepsy, diabetes, thyroid disease, autonomic dysfunction, or clinical depression. Subjects were also excluded if they reported taking any medication containing PPA, monoanaine oxidase inhibitors, or any cough, cold, or sinus product on a regular basis. Women were excluded if they were pregnant, nursing an infant, or not practicing a reliable birth control method. Those reporting any previous adverse reactions to stimulants, inability to chew gum, the use of other forms of tobacco, or participation in previous PPA studies were excluded from the current investigation. Finally, those with a pretest resting systolic blood pressure exceeding 145 mmhg or a resting diastolic exceeding 90 mmhg were not admitted into the study. The initial randomized sample of 107 subjects included 56 men and 51 women. Of the 107 subjects, 55 were unsuccessful at quitting smoking, as measured by weekly and random "spot" carbon monoxide checks (see below). In addition, five male subjects were dropped from the study due to elevated blood pressure, leaving a sample size of 47 subjects who stopped smoking for the entire month. Regarding the blood pressure exclusions, four of these subjects had been assigned to the PPA group and the remaining subject to the placebo group [Z a (1) = 2.070, P = 0.150). Analysis of the baseline data for these five individuals revealed systolic pressures that were marginally higher (mean = 133.4, SD = 4.9) than other male subjects (mean= 125.3, SD= 10.8) remaining in the trial [F(1, 54) = 2.71, P = 0.105]. Diastolic pressures were also higher in those exited from the study (mean = 76.4, SD = 8.2 versus mean = 72.5, SD=6.7) but were not statistically significant [F(1, 54) = 1.48, P = Procedure Subjects interested in study participation were contacted and administered an initial screening questionnaire over the telephone. This initial questionnaire included queries on inclusionary and exclusionary criteria. Subjects were then mailed a packet of information (i.e., description of study procedures, directions to the laboratory), along with a questionnaire on smoking behavior and on their medical history. All subjects monitored baseline withdrawal symptoms before cessation and the number of cigarettes smoked per day for a 1-week period. Upon arrival to the laboratory (approximately 10 days alter their initial phone screening), subjects were administered (via interview format) a medical screening questionnaire which again queried for all inclusionary and exclusionary criteria. Subjects reporting fulfillment of inclusionary criteria on both screenings were eligible for participation (this resulted in the exclusion of three people at orientation). Subjects' blood pressures and carbon monoxide levels were then obtained. Nine subjects whose systolic blood pressure exceeded 145 mmhg, whose diastolic blood pressure exceeded 90 mmhg, or whose carbon monoxide was less than 15 ppm were excluded from the study. Following administration of this battery, subjects were randomized into the study. Subjects then filled out demographic information, and height, body weight, smoking patterns, and smoking history information were obtained. A brief, but intensive, behavioral smoking cessation program was then delivered by trained therapists. This cessation program was a single-session, 30-rain intervention to help people quit smoking and prevent relapse. Since subjects were screened as to their willingness to quit smoking, no time was spent on preparation for quitting. The time was equally spent focusing on both quitting (e.g., removing temptations to smoke like cigarettes and ashtrays) and preventing relapse (e.g., avoiding high risk environments such as bars and dealing with temptations to smoke). Subjects were given gum containing 8.33 mg PPA per piece or an identical placebo gum in a double-blinded randomized fashion. Gums were blister-packed ten per card and boxed in cards of seven (a 1-week supply). Subjects were given instructions on gum use and told to start gum use the next morning when they quit smoking. Subjects were told to chew a piece thoroughly (30 min or more) whenever they had a cigarette craving. Subjects were told not to exceed ten pieces (or one card) per day. Assignment of product was independently randomized and group membership (e.g., gum A versus Gum B) was not revealed to the researchers until all data were coded. Identification of those using active gum was not revealed until statistical analyses were complete. Subjects were instructed to quit smoking the following day and were instructed as to dosing regimen. Subjects also continued to monitor number of cigarettes smoked (if they relapsed) and record withdrawal symptomatology. They monitored the number of pieces of gum chewed per day as well as how long each piece was chewed. Seven days later, subjects successful at abstinence returned to the laboratory with their forms. Body weight, blood pressure, and carbon monoxide levels were again obtained. Abstinent subjects were given another 7-day supply of gum and were told to continue to monitor cigarettes smoked, withdrawal symptomatology, and gum use over the next 7 days. This procedure was repeated a total of four times over a 4-week period. Subjects were exited from the study after 28 days of consecutive smoking abstinence. For adherence to treatment, subjects were paid $40, $50, $60, and $75 for abstinence at 1, 2, 3 and 4 weeks, respectively. Measures Measures of smoking status and smoking history Multiple measures of smoking status were employed in the current investigation. First, the Smoking Patterns Questionnaire (Glasgow et al. 1983) was administered at pretest. The Smoking Patterns Questionnaire produces scores on the target behaviors of nicotine content of cigarette, brand smoked, the number of cigarettes per day, and the percent of each cigarette smoked. Subjects monitored daily cigarette consumption over a 7-day baseline as well as the 4-week intervention. As the objective measure of smoking exposure, carbon monoxide (CO) in expired breath samples was collected in all smokers following the protocol outlined by Hughes et al. (1978). Subjects held their breath for 20 s and then exhaled into a small disposable balloon. The balloon was attached to a sensor that read alveolar carbon monoxide in parts per million. Subjects received CO assessments at pretest (to confirm that they were smokers) and at each weekly visit to confirm abstinence (< 8 ppm CO). Additionally, two "spot" random CO checks were collected in the field (i.e., at participants' homes or worksites) on all participants who were abstinent. Subjects had to report not smoking a single cigarette and register in the non-smoking range on all carbon monoxide assessments (four weekly visits + two spot checks) to be classified as a quitter. Resting blood pressure Pretest blood pressures were obtained at the pretest laboratory session to insure that all participants were normotensive. Nine potential participants were disqualified (six men, three women) prior to randomization, and five men were excluded after randomization. Participants were seated with a technician in a quiet room for 5 min. Using an automated blood pressure monitor (Dinamap 1846SX), two measures of blood pressure were obtained at 1-min intervals. The first reading (an acclimation reading) was discarded and the second reading was used. Anyone with a systolic blood pressure of greater than 145 mmhg or a diastolic greater than 90 mmhg was not admitted into the study.
4 88 Withdrawal symptoms checklist All subjects reported daily cigarette withdrawal symptoms, using the measure developed by Hughes and colleagues (Hughes and Hatsukami 1986; Hughes et al. 1991). The checklist is in diary format and lists several withdrawal symptoms commonly associated with smoking cessation. The symptoms coded and analyzed for this study were those that form the DSM-III-R criteria for nicotine withdrawal (i.e., cigarette craving, anger, anxiety, decreased concentration, restlessness, increased appetite, and weight gain; APA 1987). Participants rated their daily symptoms along a 10-point Likerttype scale, ranging from None (0) to Severe (9). Very high reliability and discriminant validity have been demonstrated with this measure (Hughes and Hatsukami 1986; Hughes et al. 1991). Assessment of height and weight Height and weight in subjects were assessed using a sensitive scale (Deteeto Electronic) accurate to -+ 2 oz and 1/4 inch. The unit was zero calibrated by project staff prior to each use. Adherence Gum use was monitored throughout the study on a daily recording tbrm. Subjects indicated how many pieces of gum were chewed per day and how long each piece was chewed. Unused packages of gum were returned by participants to verify reports of adherence. If discrepancies between self-reports and returned gum could not be reconciled, unused gum was used to determine number of pieces chewed. Approach to analysis Because the primary purpose of the current study was to evaluate the effects of PPA on those subjects who remained continuously abstinent from cigarettes, all analyses were conducted with the resultant sample of quit smokers. Our primary analysis involved two, multivariate repeated measures analyses of variance (MANOVA) with one analysis testing the effect of PPA on general withdrawal symptoms (e.g., craving for a cigarette, concentration) and the other MANOVA testing the variables related to weight (actual weight gain and self-reports of hunger). However, our first set of preliminary analyses (the only analyses conducted on the entire initial sample) evaluated the characteristics of those who were successful at quitting smoking versus those who were unable to quit smoking. The purpose of these analyses was to determine the characteristics of the initial versus the resultant cohort. Cessation As mentioned above, of the 107 subjects (55 placebo, 52 PPA) initially randomized into the trial (including those who subsequently left the study due to high blood pressure), 47 (44%; 28 placebo, 19 PPA) were successful in quitting smoking for the entirety of the study. There were no between-groups differences between the placebo and PPA conditions in terms of successful smoking cessation although power for this comparison was low (/~ = 0.32). Fiftyone percent of the placebo subjects were successful at quitting smoking, relative to 37% in the PPA condition. When analyzed at the point of relapse (e.g., not quit at all = 0 days; quit for all 4 weeks = 28 days), a continuous variable that will increase power, no differences were also observed between the placebo (mean point of relapse = days, SD = 12.50) and the PPA (mean point of relapse =15.10 days, SD=15.11) groups [F(1, 105)= 0.673, P = 0.41). Subjects successful at quitting smoking for 4 weeks were different from those who failed to quit on several variables. Self-reported length of the most recent quit attempt revealed significant differences between successful and unsuccessful quitters IF(l, 105)= 4.990, P = 0.028). Quitters reported having stopped smoking for a longer period of time during their most recent quit attempt (mean = days, SD = 20.80) compared to those who failed to quit smoking (mean = 5.03 days, SD = 14.98). In addition, a significantly higher proportion of successful quitters had no other smokers in their home environment compared to unsuccessful quitters [Z2(I)= 15.69, P = ]. Specifically, 70% of quitters reported no other smokers in their home environment compared to only 32% of unsuccessful quitters. Results Assessment of adverse reactions One additional preliminary set of analyses were conducted to evaluate possible increases in blood pressure and heart rate due to PPA. Apical blood pressure and heart rate following baseline (i.e., the 4 weeks following cessation) were ascertained and a change score was calculated by subtracting baseline from this apical value. Blood pressure and heart rate change were compared between treatment groups after controlling for baseline values with an analysis of covariance. Scores for those subjects who left the study because of high blood pressure were included in these analyses. Results indicated that there were no significant increases in systolic blood pressure, diastolic blood pressure, or heart rate attributable to PPA use. Adherence to treatment Although serum levels of PPA could not be collected, two proxies of adherence to treatment were collected. First, all subjects monitored daily both the number of pieces of gum chewed and the amount of time each piece was chewed. Second, to corroborate self-reports of the number of pieces chewed, subjects returned all unused gum. The average number of pieces of gum chewed among those who quit was similar between treatments [F(1,45) =0.0023, P=0.962]. The placebo group chewed an average of 8.1 (SD = 1.61) pieces of gum a day and those in the PPA condition chewed an average of 8.1 pieces (SD = 1.15). Similarly, no differences between conditions were tbund for the average length of time gum was chewed IF(l, 45) = 0.370, P = ]. The placebo condition chewed gum for an average of 5.31 (SD = 2.93) h per day and the PPA condition chewed gum for an average of 5.87 (SD = 3.25) h per day. Effects of treatment on smoking withdrawal - changes in withdrawal symptoms not related to weight To evaluate the effects of PPA on the five DSM-III-R symptoms of withdrawal not related to weight (i.e.,
5 89 cigarette craving, anger, tension, decreased concentration, and restlessness), a multivariate repeated measures analysis of variance (MANO?k) was conducted with the five withdrawal symptoms as the dependent variables, drug (placebo versus PPA) as the grouping factor and the respective symptoms at each time (1 week of baseline plus 4 weeks of cessation) as the repeated factor. It should be noted that the self-reported withdrawal symptom data were highly skewed. As such, Wilcoxon Rank Sum tests (also known as Mann- Whitney Utests) were conducted on change scores from baseline to subsequent weeks for each of the withdrawal components. Given that the results were highly consistent with those reported in the text, the more parsimonious MANOVA models were reported. The results of this analysis revealed a significant main effect for time IF(4, 180) = 6.55, P < 0.001], but no main effect for gum [F(1, 45) = 1.04, P = 0.41] and no significant gum by time interaction [F(4, 180) = 1.55, P = 0.15]. As can be seen by Table 1, consistent with several other investigations (US DHHS 1990; Hughes et al. 1991), marked increases were typically observed for the first 2 weeks of cessation, followed by sharp drops in symptoms of withdrawal in the final 2 weeks. By week 4, all symptoms were no longer significantly different from baseline levels. PPA had no effect on this relationship, as indicated by the non-significant interaction between gum and time. Effects of treatment on smoking withdrawal - changes in weight-related withdrawal symptoms To evaluate the effects of PPA on the two DSM-III-R symptoms of withdrawal that are weight related (actual weight gain and self-reports of hunger), a second mul- tivariate repeated measures analysis of variance (MANOVA) was conducted with the two weight-related withdrawal symptoms as the dependent variables, drug (placebo versus PPA) as the grouping factor and the respective symptoms at each time (1 week of baseline plus 4 weeks of cessation) as the repeated factor. Results of this MANOVA indicated a significant main effect for time [F(4, 180)= 8.00, P < ] and a significant gum by time interaction IF(4, 180) = 2.51, P < 0.027]. Simple main effects analysis using a Tukey follow-up revealed that for self-reported hunger ratings, these ratings significantly increased in the placebo group during week 1 of cessation before eventually returning to baseline. In contrast, there was no significant increase in hunger ratings in the PPA group. In terms of actual weight gain, by the end of 4 weeks of cessation, both groups had gained a significant amount of weight. However, the weight gain in the placebo group was significant after 1 week of cessation, while the weight gain in the PPA group was not significant (relative to baseline) until the final (fourth) week of treatment. Those in the PPA group had gained significantly less weight (relative to baseline) in both weeks 3 and 4 of treatment (see Table 1). When expressed as percent of body weight gained over time, the PPA group also had less change in percent weight (mean = 1.82%, SD = 1.84) compared to the placebo group [mean = 2.35%, SD = 1.71; F(1, 45) = 6.31, P < ]. Discussion The results of the current study indicate that PPA significantly reduced postcessation weight gain in a Table 1 Mean (SD) sympton scores and weight changes Baseline Week 2 Week 3 Week 4 Week 5 Cigarette craving a Placebo 4.25 (1.94) 5.94 (1.82) 4.65 (2.03) 3.70 (1.95) 3.00 (2.12) PPA 5.00 (1.42) 5.92 (1.29) 4.87 (1.55) 3.65 (1.83) 3.17 (1.77) Anger a Placebo 2.03 (1.49) 3.25 (2.19) 2.44 (2.03) 1.88 (1.54) 1.54 (1.44) PPA 2.83 (1.58) 4.40 (1.96) 3.44 (1.82) 2.47 (1.84) 1.88 (1.43) Tension a Placebo 2.28 (1,63) 3,46 (2.08) 2.48 (1.99) 1.96 (1.59) 1.81 (1,60) PPA 3.03 (1.62) 4.38 (2.03) 3.37 (1.75) 2.42 (1.88) 1.87 (1.25) Decreased concentration a Placebo 1.63 (1.34) 2.29 (1.73) 1.86 (1.76) 1.24 (1.22) 1.48 (1.53) PPA 2.01 (1.60) 3.50 (2.34) 2,00 (1.33) 1.63 (1.51) 1.31 (1.16) Restlessness Placebo 2.53 (1.89) 3.17 (1.98) 2.51 (1.96) 1.85 (1.51) 1.79 (1,70) PPA 2.94 (1.93) 4.17 (2.16) 3,14 (1.56) 2.25 (1.69) 1.69 (1.16) Ilunger a,b Placebo 2.69 (1.94) 3.52 (1.64) 2.97 (1.66) 2.50 (1.54) 1.89 (1,16) PPA 2.52 (I.29) 2.86 (1.82) 2.60 (1.45) 2,24 (1.56) 2.29 (1.59) Weight change (kg) a,b Placebo 0.49 (1.00) 0,79 (1.02) 1.13 (1.16) 1.73 (1.34) PPA 0.26 (1.09) 0.23 (0.97) 0.74 (0.77) 0.74 (1.19) adenotes a significant (P < 0.05) main effect for Time bdenotes a significant (P < 0.05) interaction between Drug Condition and Time
6 90 heterogeneous cohort of both men and women who quit smoking for 1 month. Moreover, there was evidence to indicate that PPA mollified self-reported hunger ratings. However, there was also evidence that the effects of PPA on withdrawal were hunger-and weight-specific: no significant effects of PPA on withdrawal were noted tbr any other DSM-III-R withdrawal symptom. Results indicating that PPA reduces postcessation weight gain are consistent with another double-blind, placebo-controlled study of smoking cessation in female smokers (Klesges et al. 1990). The current study indicates that these effects generalize to male smokers and to those who are not necessarily weight conscious. Moreover, there was evidence that PPA abated ratings of hunger. This finding is consistent with reported reductions in dietary intake in those receiving PPA (Klesges et al. 1990). Given that postcessation weight gain is a deterrent to smoking cessation, particularly in women (US DHHS 1988, 1990), short-term use of PPA may provide a useful adjunct to smoking cessation efforts for the weight-conscious smoker. Future research should follow smokers for a longer period of time to determine whether PPA reduces or merely delays postcessation weight gain. However, if PPA only delays postcessation weight gain (as is the case with nicotine gum; Gross et al. 1989), it is possible that PPA could be useful during the early stages of quitting, when the threat of relapse is particularly high. If, during these early stages of quitting, weight-conscious smokers are relieved of their concern about weight gain, nonsmokdng patterns could be more firmly established. Issues related to weight gain could be addressed later in the cessation process when the smoker is less likely to relapse. However, although the results showed that PPA had an effect on postcessation weight gain and ratings of hunger, it was clear that PPA did not show beneficial effects on withdrawal symptoms not related to weight. The potential implication of this finding is fairly straightforward. That is, if a smoker is concerned exclusively, or primarily, with postcessation weight gain, PPA, given its low cost, availability, and non-addictive properties, may be the drug of choice. However, if a smoker reports a large number of smoking withdrawal symptoms such as cravings for cigarettes, nicotine replacement therapy appears to be the preferential therapy. After safety issues are addressed, future researchers may want to consider combining nicotine replacement therapy with PPA. For example, the nicotine patch and nicotine gum appear to have strong, beneficial effects on most smoking withdrawal symptoms (Daughton et al. 1991; Transdermal Nicotine Study Group 1991) and are easy to use. However, reduction of postcessation weight gain is not always observed with these products, perhaps due to inadequate dosing as well as other factors (Sachs and Leischow 1991). It appears that PPA may be selective on postcessation weight gain and hunger. Perhaps combined, increased efficacy could be demonstrated, particularly in weightconscious smokers. In summar L the effects of PPA on smoking withdrawal are quite specific. PPA reduced postcessation weight gain in both men and women quitters and appeared to alleviate postcessation ratings of hunger. If future research confirms these findings, PPA may be a useful short-term pharmacologic adjunct to smoking cessation for smokers who are primarily concerned about postcessation weight gain. Acknowledgements This study was supported by two grants (HL45057, HL46352) awarded by the National Heart, Lung, and Blood Institute. We also appreciate the financial support for subject payment from Schering-Plough Corporation and fbr providing the placebo and PPA gum. Support was also received from a Centers of Excellence grant awarded to the Department of Psychology, The University of Memphis, by the state of Tennessee. The authors thank Dr. John Hughes, who was extremely helpful in providing direction for the revision of this manuscript. References APA (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised). American Psychological Association, Washington DC Camp DE, Klesges RC, Relyea G (1993) The relationship between body weight concerns and adolescent smoking. Health Psychol 12: Charlton A (1984) Smoking and weight control in teenagers. Public Health London 98 : Daughton DM, Heatley SA, Pendergast J J, Causey D, Knowles M, Rotf CN, Cheney RA, HatMid K, Thompson AB, Rennard SI (1991) Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy. A randomized, placebo-controlled, double blind study. Arch Int Med 151: Emont SL, Cummings KM (1987) Weight gain following smoking cessation: a possible role for nicotine replacement in weight management. Addict Behav 12: Glasgow RE, Klesges RC, Godding PR, Gegelman R (1983) Controlled smoking, with or without carbon monoxide feedback, as an alternative for chronic smokers. Behav Ther 14: Greenway FL (1992) Clinical studies with phenylpropanolamine: a metaanalysis. Am J Clin Nutr 55: 203S-205S Gross J, Stitzer ML, Maldonado J (1989) Nicotine replacement: effects on post-cessation weight gain. J Consult Clin Psychol 57: Hughes JR, Hatsukami D (1986) Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 43: Hughes JE, Frederiksen LW, Frazier M (t978) A carbon monoxide analyzer for measurement of smoking behavior. Behav Ther 9: Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW (1991) Symptoms of tobacco withdrawal: a replication and extension. Arch Gen Psychiatry 48:52-59 Hughes JR, Gulliver SB, Solomon LJ, Flynn BS (1992) Smoking cessation and tobacco withdrawal symptoms in self-quitters. Poster presented at: Society For Behavioral Medicine Annual Meeting, New York, New York Hunt WA, Bespalec DA (1974) An evaluation of current methods of modifying smoking behavior. J Clin Psychol 30: 431~438 Klesges RC, Ktesges LM (1988) Cigarette smoking as a dieting strategy in a university population. Int J Eating Disord 7:
7 91 Klesges RC, Klesges LM, Meyers AW, Ktem ML, Isbell T (1990) The effects of phenylpropanolamine on dietary intake, physical activity, and body weight following smoking cessation. Clin Pharmacol Ther 47: Lasagna L (1988) Phenylpropanolamine: A review. Wiley, New York Morgan JP (1986) Phenylpropanolamine: a critical analysis of reported adverse reactions and overdosage. Jack K. Burgess, Fort Lee, New Jersey Morgan JP, Kagan DV, Brody JS (eds) (1985) Phenylpropanolamine: risks, benefits, and controversies. Praeger Publishers Division, Westport, Connecticut Pirie PL, McBride CM, Hellerstedt W, Jeffery RW, Hatsukami D, Allen S, Lando H (1992) Smoking cessation in women concerned about weight. Am J Public Health 82: Sachs DPL, Leischow SJ (1991) Pharmacologic approaches to smoking cessation. Clin Chest Med 12: Schwartz JL (1987) Review and evaluation of smoking cessation methods: the United States and Canada, National Cancer Institute, US Dept. of Health and Human Services. (NIH Publ. No ), Division of Cancer Prevention, Bethesda, MD Spring B, Wurtman J, Gleason R, Wurtman, Kessler K (t991) Weight gain and withdrawal symptoms after smoking cessation: a preventive intervention using d-fenfluramine. Health Psychol 10: Spring B, Pingitore R, Kessler K (1992) Strategies to minimize weight gain after smoking cessation: psychological and pharmacological intervention with specific reference to dexfenfluramine. Int J Obes 16: Tonnesen P, Norregaard J, Simonsen K, Sawe U (1991) A doubleblind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med 325 : Transdermal Nicotine Study Group (1991) Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. JAMA 266: United States Department of Health and Human Services (1990) The Health Benefits of Smoking Cessation. A Report of the Surgeon General (DHHS Publ. No. (CDC) ). US Government Printing Office United States Department of Health and Human Services (1985) The health consequences of smoking: cancer and chronic lung disease in the workplace. A report of the Surgeon General (DHHS Publ. No. PHS ). US Government Printing Office United States Department of Health and Human Services (1988) The health consequences of smoking: nicotine addiction. A Report of the Surgeon General (DHHS Publ. No. (CDC) ). US Government Printing Office
The effects of PPA and nicotine gum on cessation rates and post cessation weight gain in women.
University of Texas at El Paso From the SelectedWorks of Theodore V. Cooper 2005 The effects of PPA and nicotine gum on cessation rates and post cessation weight gain in women. Theodore V. Cooper, University
More informationRandomized controlled trial of physical activity counseling as an aid to smoking cessation: 12 month follow-up
Addictive Behaviors 32 (2007) 3060 3064 Short communication Randomized controlled trial of physical activity counseling as an aid to smoking cessation: 12 month follow-up Michael Ussher a,, Robert West
More informationA comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler
Psychopharmacology (2000) 149:198 202 Springer-Verlag 2000 ORIGINAL INVESTIGATION Robert West Peter Hajek Jonathan Foulds Fredrik Nilsson Sylvia May Anna Meadows A comparison of the abuse liability and
More informationWanting to Get Pregnant
Continuing Medical Education COPD Case Presentation LEARNING OBJECTIVES Those completing this activity will receive information that should allow them to Assist a patient in developing a quit plan; Advise
More informationGeneral and smoking cessation related weight concerns in veterans.
University of Texas at El Paso From the SelectedWorks of Theodore V. Cooper 2006 General and smoking cessation related weight concerns in veterans. Theodore V. Cooper, University of Texas at El Paso M.
More informationSMOKING CESSATION WORKSHOP. Dr Mark Palayew December
SMOKING CESSATION WORKSHOP Dr Mark Palayew December 5 2016 Conflicts of Interest None Case 1 Mr. T is a 55 year old smoker 2 packs/day He has been smoking continuously since age 16 When he wakes up at
More informationARTICLE. Access of Over-the-counter Nicotine Replacement Therapy Products to Minors
ARTICLE Access of Over-the-counter Nicotine Replacement Therapy Products to Minors Karen C. Johnson, MD, MPH; Lisa M. Klesges, PhD; Grant W. Somes, PhD; Mace C. Coday, PhD; Margaret DeBon, PhD Background:
More informationBASIC SKILLS FOR WORKING WITH SMOKERS
BASIC SKILLS FOR WORKING WITH SMOKERS Course Description Goals and Learning Objectives 368 Plantation Street, Worcester, MA 01605 www.umassmed.edu/tobacco 2018 Basic Skills for Working with Smokers 1 Table
More informationBASIC SKILLS FOR WORKING WITH SMOKERS
BASIC SKILLS FOR WORKING WITH SMOKERS Course Description Goals and Learning Objectives 55 Lave Ave No, Worcester, MA 01655 www.umassmed.edu/tobacco 2016 Basic Skills for Working with Smokers 1 Table of
More informationSupplementary Material
Supplementary Material Supplementary Table 1. Symptoms assessed, number of items assessed, scoring, and cut-off points for the psychiatric rating scales: Montgomery Åsberg Depression Rating Scale, Hamilton
More informationEffective Treatments for Tobacco Dependence
Effective Treatments for Tobacco Dependence Abigail Halperin MD, MPH Director, University of Washington Tobacco Studies Program Ken Wassum Associate Director of Clinical Development and Support Quit for
More informationWhat is Quitline Iowa?
CONTENTS: What is Quitline Iowa? 0 A telephone counseling helpline for tobacco-use cessation. Free to all residents of the state of Iowa Open Monday-Thursday 7:00am 12:00am / Friday 7:00am 9:00pm / Saturday
More informationWeight Gain in Women after Smoking Cessation?
Can Physical Activity Minimize Weight Gain in Women after Smoking Cessation? :,:!`,:!,:,:!,:,.s Ichiro Kawachi, MD, Rebecca J. Troisi, DSc, Andrea G. Rotnitzk', PhD, Elugenie H. Coakley, MS, and Graham
More informationBiopsychosocial Treatment of Nicotine Dependency: Family Participation Versns No Partner Group Treatment
Biopsychosocial Treatment of Nicotine Dependency: Family Participation Versns No Partner Group Treatment Rey Martinez, Ph.D. Ph.D., Florida State University, 1994 Assistant Professor, University of Texas
More informationThank you Dr. XXXX; I am going to be talking briefly about my EMA study of attention training in cigarette smokers.
Thank you Dr. XXXX; I am going to be talking briefly about my EMA study of attention training in cigarette smokers. 1 This work is a result of the combined efforts of myself and my research advisor, Dr.
More informationProvision of Stop Smoking Support in Pharmacy
Public Health Agreement for the Provision of Stop Smoking Support in Pharmacy 1 st April 2017 to 31 st March 2018 BETWEEN Surrey County Council AND Pharmacy 1. Introduction 2. Aims 3. Service Outline 4.
More informationEVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO
EVIDENCE-BASED INTERVENTIONS TO HELP PATIENTS QUIT TOBACCO Lena Matthias Gray, MSA, CTTS-M University of Michigan MHealthy Tobacco Consultation Service Overview of Tobacco Use The World Health Organization
More informationORIGINAL INVESTIGATION. Randomized Comparative Trial of Nicotine Polacrilex, a Transdermal Patch, Nasal Spray, and an Inhaler
ORIGINAL INVESTIGATION Randomized Comparative Trial of Nicotine Polacrilex, a Transdermal Patch, Nasal Spray, and an Peter Hajek, PhD; Robert West, PhD; Jonathan Foulds, PhD; Fredrik Nilsson, MSc; Sylvia
More informationBackground. Abstinence rates associated with varenicline
What are the range of abstinence rates for varenicline for smoking cessation? Do they differ based on treatment duration? Are there any studies utilizing 3-4 months of varenicline treatment? Background
More informationSUSTAINED-RELEASE BUPROPION, A NICOTINE PATCH, OR BOTH FOR SMOKING CESSATION
SUSTAINED-RELEASE, A, OR BOTH FOR SMOKING CESSATION A CONTROLLED TRIAL OF SUSTAINED-RELEASE, A, OR BOTH FOR SMOKING CESSATION DOUGLAS E. JORENBY, PH.D., SCOTT J. LEISCHOW, PH.D., MITCHELL A. NIDES, PH.D.,
More informationEvaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal
Psychopharmacology (2004) 177: 195 199 DOI 10.1007/s00213-004-1923-6 ORIGINAL INVESTIGATION Robert West. Peter Hajek Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal
More informationThe Ohio State University and The Bellevue Hospital Smoking Cessation Initiative - 1. Are you finally ready to stop smoking?
The Ohio State University and The Bellevue Hospital Smoking Cessation Initiative - 1 Are you finally ready to stop smoking? If you are ready to stop smoking, you may be interested in a collaborative research
More informationASSISTING PATIENTS with QUITTING EFFECTS OF CLINICIAN INTERVENTIONS. The 5 A s. The 5 A s (cont d)
ASSISTING PATIENTS with QUITTING CLINICAL PRACTICE GUIDELINE for TREATING TOBACCO USE and DEPENDENCE Released June 2000 Sponsored by the AHRQ (Agency for Healthcare Research and Quality) of the USPHS (US
More information9/16/2016. I would feel comfortable dispensing/prescribing varenicline to a patient with a mental health disorder. Learning Objectives
The Smoking Gun: for Smoking Cessation in Patients with Mental Health Disorders BRENDON HOGAN, PHARMD PGY2 PSYCHIATRIC PHARMACY RESIDENT CTVHCS, TEMPLE, TX 09/23/2016 I would feel comfortable dispensing/prescribing
More informationUMDNJ School of Public Health. Tobacco Dependence Clinic. Annual Report: 2003
UMDNJ School of Public Health Tobacco Dependence Clinic Annual Report: 2003 January 1, 2003 December 31, 2003 2 Tobacco Dependence Clinic at UMDNJ-School of Public Health: Summary Report 2001-2003 Introduction
More informationOver the Road Truck Driver Who Smokes
Continuing Medical Education Case Presentation 1 CME Credit Physicians Physician Assistants Nurse Practitioners Over the Road Truck Driver Who Smokes RELEASE & REVIEW DATE This activity was last reviewed
More informationCigarettes and Other Nicotine Products
Cigarettes and Other Nicotine Products Nicotine is one of the most heavily used addictive drugs in the United States. In 2002, 30 percent of the U.S. population 12 and older 71.5 million people used tobacco
More informationThe 5A's are practice guidelines on tobacco use prevention and cessation treatment (4):
Smoking Cessation Module Tobacco use is the single greatest preventable cause of chronic diseases and premature deaths worldwide. The Canadian Cancer Society reports that tobacco product use is responsible
More informationCustomize Your Quit \ 2 1 / Tailored treatment to help stop smoking. Customize Your Quit. Customize Your Quit
1 / \ 2 Customize Your Quit McNeil Consumer Healthcare, division of Johnson & Johnson Inc., Markham, Canada L3R 5L2 Johnson & Johnson Inc. 2017 PSNRT15-80E Tailored treatment to help stop smoking 3 / \
More informationNorthern Tobacco Use Monitoring Survey Northwest Territories Report. Health and Social Services
Northern Tobacco Use Monitoring Survey 2004 Northwest Territories Report Health and Social Services 1.0 Introduction The Canadian Tobacco Use Monitoring Survey (CTUMS) was initiated in 1999 to provide
More informationSmoking Cessation Self-Management Plan and Care Plan
Smoking Cessation Self-Management Plan and Care Plan I understand the following items will be beneficial to the treatment of my tobacco abuse, have discussed this with my provider and I agree to implement
More informationManagement of Tobacco Dependence. Dr. Lokesh Kumar Singh Associate Professor Department of Psychiatry AIIMS, Raipur
Management of Tobacco Dependence Dr. Lokesh Kumar Singh Associate Professor Department of Psychiatry AIIMS, Raipur Difficult to identify any other condition that presents such a mix of lethality, prevalence,
More informationSmoking Reduction is the First Step Towards Smoking Cessation
Smoking Reduction is the First Step Towards Smoking Cessation Dr. SSC Chan 1, Prof. TH Lam 2, Dr. VT Wong 3, Mr. AYW Chan 4, Prof, AJ Hedley 2 1 Department of Nursing Studies, HKU LKS Faculty of Medicine
More informationIndepen dent Study On Program Effective ness
Indepen dent Study On Program Effective ness This report was prepared by the Davis-Valente Group in cooperation with the Johns Hopkins University. (NOTE: Graphs have been removed to increase Internet load
More informationInterventions for preventing weight gain after smoking cessation (Review)
for preventing weight gain after smoking cessation (Review) Parsons AC, Shraim M, Inglis J, Aveyard P, Hajek P This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More informationExecutive Summary. Context. Guideline Origins
Executive Summary Context In America today, tobacco stands out as the agent most responsible for avoidable illness and death. Millions of Americans consume this toxin on a daily basis. Its use brings premature
More informationNicotine Replacement Therapy and Brief Motivational Interview for Emergency Department Smokers with Asthma
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 3-4-2008 Nicotine Replacement Therapy and Brief Motivational Interview
More informationMYTH #1. Nicotine is a harmful, medically dangerous drug. Nicotine: Myths, Realities & Treatment OBJECTIVES FACT. CSAM Board Review Course, 10/23/08
Nicotine: Myths, Realities & Treatment CSAM Board Review Course, Newport Beach, CA Presented by David P.L. Sachs, MD Director, Palo Alto Center for Pulmonary Disease Prevention & Clinical Associate Professor,
More informationSession 1: Days 1-3. Session 4: Days Session 2: Days 4-7. Session 5: Days Session 3: Days Day 21: Quit Day!
Tobacco cessation overview calendar 21-Day Countdown to Quitting Session 1: Days 1-3 List health benefits of quitting. List expectations of overcoming your habits and addictions. List your top three Schedule
More informationPractical ways of reducing cigarette cravings. Robert West Cancer Research UK and UCL UK National Smoking Cessation Conference June 2005
Practical ways of reducing cigarette cravings Robert West Cancer Research UK and UCL UK National Smoking Cessation Conference June 2005 Outline What are cravings? The role of cravings in addiction What
More informationSmoking It s never too late to quit
Smoking It s never too late to quit Patient Education Improving Health Through Education Making a change for your health Choosing a healthy lifestyle is the best thing you can do to protect your health
More informationCigarettes and Other Tobacco Products
Cigarettes and Other Tobacco Products Tobacco use is the leading preventable cause of disease, disability, and death in the United States. According to the Centers for Disease Control and Prevention (CDC),
More informationTWIN VALLEY BEHAVIORAL HEALTHCARE CLINICAL GUIDELINES FOR MANAGEMENT OF SMOKING CESSATION
Appendix G PHASE OF MANAGEMENT NOTIFICATION ASSESSMENT TWIN VALLEY BEHAVIORAL HEALTHCARE CLINICAL GUIDELINES FOR MANAGEMENT OF SMOKING CESSATION ACTIONS All patients will be advised on admission that :
More informationUpdate on Medications for Tobacco Cessation
Update on Medications for Tobacco Cessation Marc Fishman MD Johns Hopkins University Dept of Psychiatry Maryland Treatment Centers Baltimore MD MDQuit Best Practices Conference Jan 2013 Nicotine Addiction
More informationText 1: E-Cigarettes, the solution or another risk factor?
Text 1: E-Cigarettes, the solution or another risk factor? This excerpt is from Medpage Today 'HypeWatch: E-Cigs Best Cessation Tool Ever, Really?' Published: May 20, 2014 A retrospective analysis comparing
More informationTobacco Dependence Assessment and Treatment
Tobacco Dependence Assessment and Treatment Jennifer Bluem Moran, M.A. Mayo Clinic Tobacco Treatment Specialist Certification 2013 MFMER slide-1 Outline Motivation Key treatment components Assessment issues
More informationDrug Use Evaluation: Smoking Cessation
Drug Use Research & Management Program Oregon State University, 3303 SW Bond Av CH12C, Portland, Oregon 97239-4501 Phone 503-947-5220 Fax 503-494-1082 Drug Use Evaluation: Smoking Cessation Tobacco cessation
More informationPHD THESIS STUDY ON THE USE OF THE PHARMACOLOGIC THERAPY WITH BUPROPION ON TOBACCO ABSTINENCE FOR SMOKERS WITH HIGH NICOTINE DEPENDENCE
THE UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA PHD THESIS STUDY ON THE USE OF THE PHARMACOLOGIC THERAPY WITH BUPROPION ON TOBACCO ABSTINENCE FOR SMOKERS WITH HIGH NICOTINE DEPENDENCE SCIENTIFIC COORDINATOR:
More informationYOUR GUIDE TO LIVING A SMOKE-FREE LIFE
YOUR GUIDE TO LIVING A SMOKE-FREE LIFE When it s time to quit smoking, YOU KNOW WHY. WE KNOW HOW. CONGRATULATIONS! You ve taken your first step to living a smoke-free life. In this guide, you ll find some
More informationSmoking and Nicotine Replacement Therapy (NRT) Lec:5
Smoking and Nicotine Replacement Therapy (NRT) Lec:5 Tobacco use remains the single largest preventable cause of mortality. Cigarette smoke is a complex mixture of an estimated 4800 compounds. Approximately
More informationCommon Diagnosis Codes and Tips for Coding Nicotine Use/
ICD-10 Tobacco Billing Guide ICD-10 and Tobacco Common Diagnosis Codes and Tips for Coding Nicotine Use/ Dependence Tobacco use is the leading cause of preventable disease and death in the United States,
More informationWE QUIT! Between percent of people living with HIV smoke cigarettes. Quitting is one of the biggest steps you can take to stay healthy.
WE QUIT! Between 60-70 percent of people living with HIV smoke cigarettes. Quitting is one of the biggest steps you can take to stay healthy. People living with HIV/ AIDS who smoke tobacco now lose more
More information5. Offer pharmacotherapy to all smokers who are attempting to quit, unless contraindicated.
0 11 Key Messages 1. Ask and document smoking status for all patients. 2. Provide brief advice on quit smoking at every visit to all smokers. 3. Use individual, group and telephone counselling approaches,
More informationWHY SHOULD CIGARETTE SMOKERS THINK ABOUT QUITTING?
How to Help Yourself Quit Smoking WHY SHOULD CIGARETTE SMOKERS THINK ABOUT QUITTING? One in three smokers dies early because of their smoking. They die of heart disease, stroke, cancer and emphysema. At
More informationDeclaration of Conflict of Interest. No potential conflict of interest to disclose with regard to the topics of this presentations.
Declaration of Conflict of Interest No potential conflict of interest to disclose with regard to the topics of this presentations. Clinical implications of smoking relapse after acute ischemic stroke Furio
More informationEnsuring Medicaid Coverage of Tobacco Cessation
Ensuring Medicaid Coverage of Tobacco Cessation Why is Medicaid Coverage of Tobacco Cessation Important? In 2014, 32 percent of Medicaid enrollees were smokers, compared with 17 percent of the general
More informationSmoking Cessation. May
Smoking Cessation Dear Colleague: The impact of smoking, especially for those with chronic illness, is known and staggering. Currently, there are 46.6 million smokers in the U.S., where tobacco use is
More information1973: No-smoking sections introduced. 1990: No-smoking on all U.S. domestic flights
Going Smoke Free 1 Going Smoke Free in STAGES 1973: No-smoking sections introduced. 1990: No-smoking on all U.S. domestic flights under 6 hours 2 Going Smoke Free in STAGES All Hospital locations in Michigan
More informationCompensatory smoking from gradual and immediate reduction in cigarette nicotine content
Compensatory smoking from gradual and immediate reduction in cigarette nicotine content Dorothy K. Hatsukami, 1 Eric C. Donny, 2 Joseph S. Koopmeiners, 3 Neal L. Benowitz 4 1 University of Minnesota, Tobacco
More informationPredictors of smoking cessation among Chinese parents of young children followed up for 6 months
Title Predictors of smoking cessation among Chinese parents of young children followed up for 6 months Author(s) Abdullah, ASM; Lam, TH; Loke, AY; Mak, YW Citation Hong Kong Medical Journal, 2006, v. 12
More informationEffect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt
Psychopharmacology (2008) 197:371 377 DOI 10.1007/s00213-007-1041-3 ORIGINAL INVESTIGATION Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking
More informationIncrease in common cold symptoms and mouth ulcers following
Increase in common cold symptoms and mouth ulcers following smoking cessation Michael Ussher*, Robert West *, Andrew Steptoe **, Andy McEwen* *Department of Psychology, Hunter Wing, St. George's Hospital
More informationSmoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial
Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial D P Tashkin, R Kanner, W Bailey, S Buist, P Anderson, M A Nides, D Gonzales,
More information3. Chantix [package insert]. New York, NY: Pfizer, Inc,; Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine
How can there be a warning regarding concomitant use of varenicline with nicotine replacement therapy yet patients can be on varenicline and smoke concurrently? April 20, 2017 The United States (US) Preventive
More informationModifications to Labeling of Nicotine Replacement Therapy Products for Over-the-Counter
This document is scheduled to be published in the Federal Register on 04/02/2013 and available online at http://federalregister.gov/a/2013-07528, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationELISSA C. KRANZLER. Annenberg School for Communication University of Pennsylvania
ELISSA C. KRANZLER Annenberg School for Communication elissa.kranzler@asc.upenn.edu EDUCATION Ph.D. Candidate (ABD), Communication Annenberg School for Communication Expected graduation, May 2018 Dissertation:
More informationAHEC Tobacco Online Modules
AHEC Tobacco Online Modules www.aheceducation.com This program is sponsored by the Florida AHEC Network and the Florida Department of Health. In July 2007, the Florida legislature appropriated funds to
More informationBOOK 3: LIVING SMOKE-FREE
BOOK 3: LIVING SMOKE-FREE Start reading this book on your Quit Day. The information in this book will help you stay smoke-free. Read through it over the next few days. It is divided into five sections.
More informationSmoking Cessation. Hassan Sajjad Pulmonary & Critical Care
Smoking Cessation Hassan Sajjad Pulmonary & Critical Care Objectives Burden of Smoking Health Impacts of Smoking Smoking Cessation Motivational Interviewing Nicotine Replacement Therapy Bupropion Varenicline
More informationCancer Control Office YOUR GUIDE TO QUIT SMOKING
Cancer Control Office YOUR GUIDE TO QUIT SMOKING ARE YOU THINKING ABOUT QUITTING SMOKING? IF YOU ARE, CONGRATULATIONS FOR TAKING THIS IMPORTANT STEP! This brochure will help you: Set your own reasons to
More informationSMS USA PHASE ONE SMS USA BULLETIN BOARD FOCUS GROUP: MODERATOR S GUIDE
SMS USA PHASE ONE SMS USA BULLETIN BOARD FOCUS GROUP: MODERATOR S GUIDE DAY 1: GENERAL SMOKING QUESTIONS Welcome to our online discussion! My name is Lisa and I will be moderating the session over the
More informationSupplementary Online Content
Supplementary Online Content Baker TB, Piper ME, Stein JH, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a randomized clinical
More informationRelapse Prevention. Jennifer S. B. Moran, MA, TTS MFMER slide-1
Relapse Prevention Jennifer S. B. Moran, MA, TTS 2013 MFMER slide-1 Learning Objectives Describe cognitive, behavioral, and pharmacologic relapse prevention concepts that may be introduced early in a tobacco
More informationBackground and Analysis Objectives Methods and Approach
Cigarettes, Tobacco Dependence, and Smoking Cessation: Project MOM Final Report Lorraine R. Reitzel, Ph.D., The University of Texas, MD Anderson Cancer Center Background and Analysis Objectives Background.
More information4 INSTRUCTOR GUIDELINES
STAGE: Recent Quitter You are a clinician working on the vascular surgery service and are about to discharge Mr. McCray, a 58-year-old patient who recently underwent a femoral artery bypass graft for peripheral
More informationQuit smoking to get the best from your cancer treatment
Quit smoking to get the best from your cancer treatment Princess Margaret For people who are smoking or using tobacco before or during cancer treatment Read this pamphlet to know how: Smoking during cancer
More informationGuidelines for. Nicotine Replacement Therapy. Issuing of Vouchers. For use by the Stop Smoking in Pregnancy Service
Guidelines for Nicotine Replacement Therapy Issuing of Vouchers For use by the Stop Smoking in Pregnancy Service DOCUMENT CONTROL: Version: 1 Ratified by: Clinical Effectiveness Committee Date ratified:
More informationReducing Tobacco Use and Secondhand Smoke Exposure: Incentives and Competitions to Increase Smoking Cessation Among Workers
Reducing Tobacco Use and Secondhand Smoke Exposure: Incentives and Competitions to Increase Smoking Cessation Among Workers Summary Evidence Table Studies of Incentives and Competitions When Implemented
More informationExamples of what to say when intervening with smoking clients. Do you smoke cigarettes or tobacco at all, or have you ever smoked regularly?
Manual of Smoking Cessation Andy McEwen, Peter Hajek, Hayden McRobbie & Robert West 2006 by McEwen, Hajek, McRobbie and West Appendix 5 Examples of what to say when intervening with smoking clients Below
More informationHow to Design a Tobacco Cessation Insurance Benefit
How to Design a Tobacco Cessation Insurance Benefit All tobacco users need access to a comprehensive tobacco cessation benefit to help them quit. A comprehensive tobacco cessation benefit includes: Nicotine
More informationCHAPTER 27: BEHAVIOR ANALYSIS AND TREATMENT OF DRUG ADDICTION
CHAPTER 27: BEHAVIOR ANALYSIS AND TREATMENT OF DRUG ADDICTION Fisher ch.27 Drug addiction is a very prevalent issue in the current United States society. The substance abuse treatments that are available
More informationSmoking Cessation for Persons with Serious Mental Illness
Smoking Cessation for Persons with Serious Mental Illness MDQuit Best Practices Conference January 22, 2009 Faith Dickerson, Ph.D., M.P.H. Sheppard Pratt Health System Lisa Dixon, M.D., M.P.H. Melanie
More informationAfter the Last Cigarette
After the Last Cigarette Treatment Options for Quitting Tobacco By Susan Kahler, MBA, CTTS Risks from Smoking The Highly Engineered Product Nicotine Delivered by Inhalation Characteristics of Nicotine
More informationTobacco dependence: Implications for service provision
Tobacco dependence: Implications for service provision Andy McEwen, PhD University College London & National Centre for Smoking Cessation and Training (NCSCT) Tuesday 29th January 2013 Cardiff Conflict
More informationPharmacotherapy Safety and Efficacy in Adolescent Smoking Cessation
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Pharmacotherapy Safety and Efficacy in
More informationNICOTINE ADDICTION Inside Looking out to Outside Looking in
NICOTINE ADDICTION Inside Looking out to Outside Looking in Marshall L. Post, BHS, RRT, AE-C Respiratory Therapist 1 What is nicotine? A colorless, poisonous alkaloid derived from the tobacco plant It
More informationIMPROVING WORKSITE WELLNESS
IMPROVING WORKSITE WELLNESS WE KNOW WORKSITE WELLNESS IS IMPORTANT TO YOUR COMPANY OR ORGANIZATION. WELLNESS MEANS: Fewer work days lost More productive staff members Lower healthcare and health insurance
More informationSmoking Cessation. Disclosures. Thank You. None
Smoking Cessation Dr. Jamie Kellar; BSc, BScPhm, PharmD Clinician Educator Centre for Addiction and Mental Health Assistant Professor Leslie Dan Faculty of Pharmacy Disclosures None Thank You Several slides
More informationUMASS TOBACCO TREATMENT SPECIALIST CORE TRAINING
UMASS TOBACCO TREATMENT SPECIALIST CORE TRAINING Course Description Goals and Learning Objectives 55 Lake Ave North, Worcester, MA 01655 www.umassmed.edu/tobacco 1 Table of Contents Determinants of Nicotine
More informationSmoking Patient Education Module
Smoking Patient Education Module Quitting smoking is difficult but is important for your health. This packet has information to help you learn the reasons to quit smoking, advice on how to quit smoking
More informationTobacco Cessation, E- Cigarettes and Hookahs
Objectives Tobacco Cessation, E- Cigarettes and Hookahs Discuss evidence-based tobacco cessation interventions including pharmacologic options. Review e-cigarette and hookah facts and safety considerations.
More informationImpact of UNC Health Care s Tobacco-Free Hospital Campus Policy on Hospital Employees
Impact of UNC Health Care s Tobacco-Free Hospital Campus Policy on Hospital Employees February 5, 2008 Prepared for: UNC Health Care Prepared by: UNC School of Medicine Nicotine Dependence Program For
More informationBest Practice for Smoking Cessation: Pharmacotherapy. Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree
Best Practice for Smoking Cessation: Pharmacotherapy Emma Dean Acting Population Health and Health Promotion Coordinator Lead Pharmacist- Smokefree Why is it so hard to quit? People who smoke aren t weak
More informationSmoking Cessation A Clinicians Perspective. Jeff Wilson, MD
Smoking Cessation A Clinicians Perspective Jeff Wilson, MD Overview Tobacco control what we have accomplished and the road ahead Role of the health care professional Using pharmacotherapy Electronic cigarettes
More informationCore Competencies - Smoking Cessation Fundamentals
Core Competencies - Smoking Cessation Fundamentals This training standard was developed for the National Training Service (NTS) Alliance in consultation with subject matter experts. The purpose of this
More informationIf You Smoke And Are Pregnant
If You Smoke And Are Pregnant Or Thinking About Pregnancy, Use This Self-help Guide TAKE THE FIRST STEP FOR YOUR BABY If You Smoke And Are Pregnant PRINT.indd 1 TAKE THE FIRST STEP FOR YOUR BABY Having
More informationStop Smoking Journal Quit Smoking Planner A Stop Smoking Planner Tracker And Journal Volume 1
Stop Smoking Journal Quit Smoking Planner A Stop Smoking Planner Tracker And Journal Volume 1 We have made it easy for you to find a PDF Ebooks without any digging. And by having access to our ebooks online
More informationWhy Tobacco Cessation?
Tobacco Cessation in Community Settings Introduction Hello and welcome to the Learning and Action Network event, Reaching Those in Need of Tobacco Cessation in Community Settings: Research, Recommendations
More informationASK Ask ASK about tobacco use ADVISE HANDOUT
ASSISTING PATIENTS with QUITTING A Transtheoretical Model Approach CLINICAL PRACTICE GUIDELINE for TREATING TOBACCO USE and DEPENDENCE Released June 2000 Sponsored by the Agency for Healthcare Research
More informationQUIT FOR YOU. QUIT FOR YOUR BABY!
My quit smoking date: ( Month / Day / Year) QUIT FOR YOU. QUIT FOR YOUR BABY! My baby s due date: ( Month / Day / Year) I AM QUITTING SMOKING FOR A LITTLE REASON Self-Help Guide to Quit Smoking for Pregnant
More information